Karolinska Development AB (publ) (0P3C.L)
Chart Events
Performance Outlook
| Previous Close | 2.6277 |
| Open | 2.6600 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 2.6600 - 2.6600 |
| 52 Week Range | 2.6600 - 2.6600 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | 0.03 |
| EPS (TTM) | 0.8910 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 0P3C.L
Related Research
- GlobeNewswire
Karolinska Development’s portfolio company Umecrine Cognition recruits Anders Karlsson as the new CEO
STOCKHOLM, SWEDEN – August 10, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the Board of Directors of the portfolio company Umecrine Cognition has recruited Anders Karlsson as the new CEO. He succeeds Magnus Doverskog, who moves on to a position as Chief Scientific Officer in the company. The recruitment aims to strengthen and broaden the management team with additional competence in business development and commercialization for the next phase in the company’s d
- GlobeNewswire
Karolinska Developments portfolio company Promimic and Danco Medical form a joint venture for the US-market
STOCKHOLM, SWEDEN, July 22 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic and the US-based company Danco Medical form a joint venture for the Processing of Medical Implants in the US market. The strategic initiative is expected to have a major impact on Promimic’s growth and profitability as early as next year. Danco Medical has been Promimic’s partner in the US since 2016 and the companies are now deepening their collaboration furthe
- GlobeNewswire
Karolinska Development expands its portfolio following an investment in PharmNovo
STOCKHOLM, SWEDEN, July 4, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) has completed a previously announced investment in PharmNovo, thereby including it among its portfolio companies. As of July 4, Karolinska Development’s investment portfolio consists of ten companies. Karolinska Development has invested SEK 20 million in PharmNovo, within the framework of a new share issue led by Sciety that in total contributed approximately SEK 67 million to the company. PharmNovo is developing
